Pages that link to "Q68974825"

The following pages link to Quantitation of neutralization of interferon by antibody (Q68974825):

Displaying 42 items.

• Anti-human herpesvirus 6A/B IgG correlates with relapses and progression in multiple sclerosis (Q28245682) (← links)
• Human leukocyte antigen genes and interferon beta preparations influence risk of developing neutralizing anti-drug antibodies in multiple sclerosis (Q28540630) (← links)
• Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis (Q28553133) (← links)
• Neutralizing antibodies explain the poor clinical response to interferon beta in a small proportion of patients with multiple sclerosis: a retrospective study (Q33510256) (← links)
• The neutralization of interferons by antibody III. The constant antibody bioassay, a highly sensitive quantitative detector of low antibody levels (Q34207663) (← links)
• Quantification of the neutralization of cytokine biological activity by antibody: the ten-fold reduction bioassay of interleukin-6 as growth factor (Q34207914) (← links)
• MHC2TA mRNA levels and human herpesvirus 6 in multiple sclerosis patients treated with interferon beta along two-year follow-up. (Q34421060) (← links)
• Serum interferon (IFN)-neutralizing antibodies and bioactivities of IFNs in patients with severe type II essential mixed cryoglobulinemia. (Q34579182) (← links)
• A comparison of the mechanisms of action of interferon beta and glatiramer acetate in the treatment of multiple sclerosis (Q35064496) (← links)
• Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. (Q35468206) (← links)
• Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon beta-1a (Rebif) treatment trial (Q35475689) (← links)
• Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies. (Q35483221) (← links)
• Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results (Q36272813) (← links)
• Atypical Porcine Type I Interferon. Biochemical and Biological Characterization of the Recombinant Protein Expressed in Insect Cells (Q36686309) (← links)
• Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report (Q36801041) (← links)
• Use of a standardized MxA protein measurement-based assay for validation of assays for the assessment of neutralizing antibodies against interferon-β. (Q37272709) (← links)
• Molecular and functional characterization of turkey interferon (Q39872881) (← links)
• Chicken-embryo fibroblasts produce two types of interferon upon stimulation with Newcastle disease virus (Q41100976) (← links)
• The incidence and clinical significance of antibodies to interferon-a in patients with solid tumors (Q41567251) (← links)
• The expression of potency of neutralizing antibodies for interferons and other cytokines (Q41567754) (← links)
• Distinct Effect of pH 2 on a Common Antigenic Structure Found in Human Interferons-α1 and -α2 in the Region 30–35 (Q41655068) (← links)
• Blood lymphocyte subsets identify optimal responders to IFN-beta in MS. (Q42516732) (← links)
• Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C. Comparison of alanine aminotransferase normalization versus loss of HCV RNA and anti-HCV IgM. (Q43048315) (← links)
• The impact of neutralizing antibodies on the risk of disease worsening in interferon β-treated relapsing multiple sclerosis: a 5 year post-marketing study (Q43520925) (← links)
• A sensitive antiviral neutralization bioassay for measuring antibodies to interferons (Q43850371) (← links)
• Mapping of two immunodominant structures on human interferon alpha 2c and their role in binding to cells (Q44132267) (← links)
• Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years (Q44883901) (← links)
• Interferon antibodies may negate the antiviral effects of recombinant alpha-interferon treatment in patients with chronic hepatitis B virus infection (Q45849818) (← links)
• Neutralising and binding anti-interferon-β-1 b (IFN-b-1 b) antibodies during IFN-β-1 b treatment of multiple sclerosis (Q48686221) (← links)
• The role of neutralizing antibodies to interferon-β as a biomarker of persistent MRI activity in multiple sclerosis: a 7-year observational study (Q51725413) (← links)
• Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis (Q51964774) (← links)
• Neutralization of the biological activity of cytokines and other protein effectors by antibody: theoretical formulation of antibody titration curves in relation to antibody affinity. (Q52009627) (← links)
• Anti-Interferon Alpha Antibodies in Patients with High-Risk BCR/ABL-Negative Myeloproliferative Neoplasms Treated with Recombinant Human Interferon-α. (Q52564132) (← links)
• Comparison of three PCR assays for the evaluation of interferon-beta biological activity in patients with multiple sclerosis. (Q53863939) (← links)
• One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients. (Q54397597) (← links)
• Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies (Q57632337) (← links)
• Enhancement of neutralizing efficacy by combining three monoclonal antibodies to human interferon-alpha (Q67691213) (← links)
• Antibodies to lymphoblastoid interferon (Q69373330) (← links)
• Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b (Q73094214) (← links)
• Effect of IFNbeta and anti-IFNbeta antibodies on NK cells in multiple sclerosis patients (Q73539370) (← links)
• Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations (Q74147656) (← links)
• Drug Holiday of Interferon Beta 1b in Multiple Sclerosis: A Pilot, Randomized, Single Blind Study of Non-inferiority (Q92403962) (← links)